Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy
ACS Omega · 19.11.2026
DOI: 10.1021/acsomega.6c07252 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 19.11.2026. Verfasst von Xiaoyuan Guo und 3 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Municipal Health Bureau, Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds.
Abstract (Originalsprache)
Temozolomide (TMZ)-based chemotherapy for glioblastoma (GBM) is severely limited by the blood–brain barrier (BBB) and the highly immunosuppressive tumor microenvironment (TME). Ganoderma lucidum spore oil (GSO) has TME-remodeling capacity, but its efficient delivery to the brain remains challenging. Here, we developed a TMZ and GSO coloaded microemulsion (TMZ&GSO-MEs) optimized for intranasal nose-to-brain delivery. Using an “active ingredient-as-excipient” design, GSO partially replaced the conventional oil phase, resulting in a uniform nanoscale formulation (∼35 nm), high encapsulation efficiency (92.6%), and sustained release. TMZ&GSO-MEs significantly enhanced cellular uptake of both TMZ and GSO and exhibited superior antiproliferative activity in GL261 cells compared to free TMZ. In an orthotopic Luc-GL261 glioma model, intranasal administration of TMZ&GSO-MEs markedly suppressed tumor growth (inhibition rate 66.5%) and extended survival (25% of mice alive at day 60). Mechanistically, GSO reprogrammed the TME by increasing M1-type tumor-associated macrophages, CD8+ T cells, and activated dendritic cells, while decreasing M2-type macrophages and TGF-β1 and shifting serum cytokines toward a Th1-dominant profile. Notably, the formulation showed a favorable safety profile with no significant body weight loss or hepatorenal toxicity. Collectively, this nose-to-brain microemulsion integrates enhanced intracranial delivery, chemo-immunotherapeutic synergy, and reduced toxicity, offering a promising strategy for GBM therapy.
Förderung
- Nanjing Municipal Health Bureau
- Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds
Zitieren
APA
Guo, X., Jin, X., Zhang, Z., & Liu, H. (2026). Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy. ACS Omega. https://doi.org/10.1021/acsomega.6c07252
Vancouver
Guo X, Jin X, Zhang Z, Liu H. Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy. ACS Omega. 2026. doi:10.1021/acsomega.6c07252
BibTeX
@article{Guo2026,
author = {Guo, Xiaoyuan and Jin, Xingxing and Zhang, Zhibo and Liu, Hongmei},
title = {Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy},
journal = {ACS Omega},
year = {2026},
doi = {10.1021/acsomega.6c07252}
}
EUVIMED